[Retention of two central biogenic amines during pharmacologic trials of a synthetic cardiovascular agent, carbamoyl-oxy-4 (fluoro-4-phenyl) (-4-oxo-4-butyl)-decahydroquinolinechlorhydrate, or L7810].
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001933:Brain Stem / Q000378:metabolism; D002090:Butyrophenones / Q000008:administration & dosage / Q000494:pharmacology*; D004027:Diencephalon / Q000378:metabolism; D005470:Fluorometry; D009638:Norepinephrine / Q000378:metabolism*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000378:metabolism*; D013687:Telencephalon / Q000378:metabolism; D013997:Time Factors; D014316:Tritium; D014851:Wakefulness / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D002090:Butyrophenones; D011804:Quinolines; D014316:Tritium; D012701:Serotonin; D009638:Norepinephrine
La rétention de deux amines biogènes centrales au cours d'essais pharmacologiques sur un cardiovasculaire de synthèse, le chlorhydrate de carbamoyl-oxy-4 (fluoro-4-phényl)(-4-oxo-4-butyl)-l-décahydroquinoléine ou L 7810